In contrast, Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) both jumped on today's news. They rose 2.7% and 7%, ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...

Eli Lilly launched its diabetes and weight-loss drug Mounjaro in India, ahead of Novo Nordisk, aiming at a market grappling ...

Eli Lilly says it is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP and ...

US-based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with ...

Lilly beats Novo Nordisk to launch weight-loss drug in India Mounjaro's 5 mg vial priced at around $50, 2.5 mg at about $40 Drug's pricing may limit accessibility in India, analyst says Novo's ...

Eli Lilly and Novo Nordisk have scored big wins from the FDA in recent months, as the agency cracks down on copycat versions of their GLP-1 blockbusters. Now, as the battle with compound GLP-1s comes ...

Zerodha’s Nithin Kamath sparks debate on Ozempic, Mounjaro & their game-changing impact on obesity, addiction & industries. Is India ready for this shift?

The much-awaited launch of Mounjaro, an injectable drug used to treat obesity, overweight, and type 2 diabetes, has been ...